Sponsor or institution
Clinical trials and research at Suzhou Immunofoco Biotechnology Co., Ltd
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Suzhou Immunofoco Biotechnology Co., Ltd that are recruiting, in China. By phase: Early Phase 1 (2), Phase 3 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Car-T therapy targeting EpCAM in advanced epithelial cancers | Phase 1/2 | Beijing | Recruiting | Jun 12, 2026 |
| IMV102 treatment for relapsed or refractory multiple myeloma | Early Phase 1 | Beijing and 3 other locations | Recruiting | Mar 25, 2026 |
| IMV101 for relapsed or refractory CD19-positive B‑cell non‑Hodgkin lymphoma | Early Phase 1 | Beijing, Beijing Municipality and 3 other locations | Recruiting | Jan 29, 2026 |
| Randomized Phase III treatment for CLDN18.2-positive unresectable locally advanced or metastatic gastric cancer | Phase 3 | Beijing | Recruiting | Aug 5, 2025 |
All recruiting trials (4)
-
Car-T therapy targeting EpCAM in advanced epithelial cancers
This study tests autologous EpCAM CAR-T cells in adults with advanced epithelial solid tumors to see if it is safe and can help fight the cancer.
-
IMV102 treatment for relapsed or refractory multiple myeloma
This trial will try a single infusion of IMV102 in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies to see if it is safe and helps control the cancer.
-
IMV101 for relapsed or refractory CD19-positive B‑cell non‑Hodgkin lymphoma
This trial tests IMV101 to see if it is safe and can shrink tumors in adults with relapsed or refractory CD19‑positive B‑cell non‑Hodgkin lymphoma who have had multiple prior treatments.
-
Randomized Phase III treatment for CLDN18.2-positive unresectable locally advanced or metastatic gastric cancer
This trial will try IMC002 CAR T-cell therapy versus the doctor's choice of treatment for adults with CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have had at least two prior treatments.
Quick answers
How many clinical trials run by Suzhou Immunofoco Biotechnology Co., Ltd are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 2, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.